Leerink Partnrs Has Negative Forecast for EW Q3 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Research analysts at Leerink Partnrs cut their Q3 2025 earnings estimates for Edwards Lifesciences in a research report issued to clients and investors on Wednesday, December 4th. Leerink Partnrs analyst M. Kratky now anticipates that the medical research company will post earnings of $0.60 per share for the quarter, down from their prior estimate of $0.62. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.56 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ Q4 2025 earnings at $0.61 EPS, FY2025 earnings at $2.43 EPS and FY2026 earnings at $2.84 EPS.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter in the previous year, the business posted $0.59 earnings per share. The business’s quarterly revenue was up 8.9% compared to the same quarter last year.

Several other research analysts have also recently commented on the stock. Royal Bank of Canada boosted their price target on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a report on Thursday, December 5th. UBS Group lowered their price target on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a report on Tuesday, September 10th. Truist Financial reiterated a “hold” rating and set a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Citigroup reduced their price objective on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research report on Tuesday, October 1st. Finally, Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Seventeen investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus price target of $78.35.

Edwards Lifesciences Trading Down 0.9 %

NYSE EW opened at $70.91 on Monday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 52 week low of $58.93 and a 52 week high of $96.12. The stock has a market capitalization of $41.82 billion, a PE ratio of 10.23, a price-to-earnings-growth ratio of 3.52 and a beta of 1.12. The firm has a 50 day moving average of $68.75 and a two-hundred day moving average of $74.29.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. This represents a 9.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,000 shares of company stock worth $2,657,000 in the last 90 days. 1.27% of the stock is owned by insiders.

Hedge Funds Weigh In On Edwards Lifesciences

A number of large investors have recently bought and sold shares of EW. Stableford Capital II LLC grew its stake in shares of Edwards Lifesciences by 2.7% during the 2nd quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company’s stock worth $533,000 after purchasing an additional 159 shares during the period. Purus Wealth Management LLC grew its stake in shares of Edwards Lifesciences by 5.2% during the 2nd quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock worth $297,000 after purchasing an additional 160 shares during the period. Busey Bank grew its stake in shares of Edwards Lifesciences by 1.9% during the 2nd quarter. Busey Bank now owns 8,838 shares of the medical research company’s stock worth $816,000 after purchasing an additional 165 shares during the period. Commerzbank Aktiengesellschaft FI grew its stake in shares of Edwards Lifesciences by 7.4% during the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 2,415 shares of the medical research company’s stock worth $224,000 after purchasing an additional 166 shares during the period. Finally, JFS Wealth Advisors LLC grew its stake in shares of Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after purchasing an additional 166 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.